Results 151 to 160 of about 15,165 (218)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5915-5925, July 2026.
ABSTRACT Aims Petrelintide is a long‐acting amylin analogue in development for weight management. The safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide were evaluated in single ascending dose (SAD) and multiple ascending dose (MAD) trials. Materials and Methods Both trials were randomized, placebo‐controlled, and double‐blind.
Minna Brændholt Olsen, Jon Griffin, Ulrike Hövelmann, Stanislava Macura, Berith Fredsted Hagen, Dan Hesse, Tim Heise   +6 more
wiley   +1 more source

Impact of Simulated Risk Factor Management on Cardiovascular Disease and Costs in Type 2 Diabetes Using the ABC Model

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5670-5683, July 2026.
ABSTRACT Aims We evaluated the impact of scenario‐based multifactorial control on the 3‐year incidence of fatal/non‐fatal cardiovascular disease (CVD) and associated healthcare costs in Asian patients with type 2 diabetes (T2D). Materials and Methods We applied the validated ‘ABC’ model to simulate the 3‐year impact of attaining multiple treatment ...
Lee‐Ling Lim, Eric S. H. Lau, Juliana N. M. Lui, Linong Ji, A. G. Unnikrishnan, Sirinart Sirinvaravong, Siew‐Pheng Chan, Soo Lim, Andrea O. Y. Luk, Juliana C. N. Chan   +9 more
wiley   +1 more source

Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions.

Use of glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, initially developed as glucose-lowering therapies for the management of type 2 diabetes, continues to expand in parallel with our ...
Neumiller, Joshua J, Alicic, Radica
core   +1 more source

Tirzepatide and Weight Management

JK Science
Tirzepatide is a once-weekly dual agonist, that acts on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
Vishal R. Tandon, Annil Mahajan
doaj  

Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5787-5802, July 2026.
ABSTRACT Aims Young adults (aged ≤ 40 years) are underrepresented in clinical trials that investigate interventions for those living with Type 2 diabetes (T2D). This study evaluated the efficacy of semaglutide treatment in young adults with T2D by examining the effects on HbA1c and body weight (BW) during the SUSTAIN and PIONEER programmes compared to ...
Francesco Zaccardi, Vanita R. Aroda, Ecenur Guder Arslan, Lars Bardtrum, Jonathan Goldney, Erik Ising, Prachi Priyadarshini, Tommy Slater, Melanie J. Davies   +8 more
wiley   +1 more source

Interaction between fatty pancreas disease and genetically predicted glucose-dependent insulinotropic polypeptide on incident type 2 diabetes: evidence from the UK Biobank. [PDF]

Front Endocrinol (Lausanne)
Wang X, Yang Y, Han S, Liu Z, Ping F, Li W, Xu L, Zhang H, Li Y.   +8 more
europepmc   +1 more source

Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6162-6171, July 2026.
ABSTRACT Aims Tirzepatide, an injectable glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) receptor agonist (RA), is approved for weight management in several regions. Oral GLP‐1 RAs, such as semaglutide, are under investigation to improve convenience, acceptance and adherence versus injectable formulations ...
Andreea Ciudin, Erin Johansson, Sarah Zimner‐Rapuch, Georgios K. Dimitriadis, Mathias Hempfling, Laura J. Clark, Ludi Fan, Helene Sapin   +7 more
wiley   +1 more source

Glucose-Dependent Insulinotropic Polypeptide Receptors Are Expressed in the Lateral Septum and Reduce Electrically-Evoked Dopamine Release as well as the Ability of Cocaine to Increase Extracellular Dopamine. [PDF]

ACS Chem Neurosci
Buchanan AM, Virkus S, Fitzgerald ND, Hernandez CE, Habegger KM, Day J, Hackett TA, Hardaway JA, Galli A.   +8 more
europepmc   +1 more source

Dietary Strategies and Nutritional Management in Patients Receiving GLP‐1 and Dual GIP/GLP‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5492-5507, July 2026.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual GIP/GLP‐1 RAs are widely used to manage obesity, prediabetes and type 2 diabetes, typically in combination with lifestyle interventions. Their nutritional implications, however, remain unclear.
Rayanne Santos de Paulo, Dandara Baia Bonifácio, Matheus Henrique Lana de Carvalho, Josefina Bressan   +3 more
wiley   +1 more source

Glucose-Dependent Insulinotropic Polypeptide and Glucagon After Weight Loss Induced by Diet or Bariatric Surgery. [PDF]

Obesity (Silver Spring)
Finn A, Cedillo Y, Aukan M, Gower B, Martins C.   +4 more
europepmc   +1 more source